As a model to study regulated RNA processing of pre-mRNAs in eukaryotic cells, we are studying viral cis elements and host trans-acting factors required for proper RNA processing and replication of Rous sarcoma virus (RSV). RSV primary transcripts are spliced and polyadenylated by the host RNA processing machineries to generate env/src mRNA, but the process must be controlled since the virus requires that a majority (75%) of the RNA remain unspliced to serve as mRNA for the gag-pol proteins and as genomic RNA for progeny virions. A novel RNA element (the NRS) that binds numerous splicing factors is required for accumulation of appropriate unspliced RNA levels and also for proper polyadenylation. NRS mutations can lead to replication defects due to oversplicing and to pathogenesis from the increased production of poly(A) read-through transcripts that play a role in oncogenesis via insertional activation.
Aim I will investigate the role of various factors in NRS splicing inhibition and explore mechanisms of inhibition involving novel, inappropriate snRNP interactions.
In Aim II, cis elements and trans factors that mediate efficient snRNP binding to the NRS will be studied.
In Aim lll, the role of the NRS in promoting efficient polyadenylation will be investigated.
In Aim I V, the function of a second splicing suppressor (SSS) associated with the src 3' splice site will be studied.
These Aims are significant in that they will enhance our understanding of control of critical RNA processing steps required for viral replication and pathogenesis, and the RSV system provides a powerful tool for dissecting novel cellular mechanisms of RNA processing regulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA078709-06
Application #
6681255
Study Section
Special Emphasis Panel (ZRG1-VR (02))
Program Officer
Cole, John S
Project Start
1998-08-14
Project End
2008-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
6
Fiscal Year
2003
Total Cost
$282,000
Indirect Cost
Name
Medical College of Wisconsin
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Hudson, Stephen W; McNally, Lisa M; McNally, Mark T (2016) Evidence that a threshold of serine/arginine-rich (SR) proteins recruits CFIm to promote rous sarcoma virus mRNA 3' end formation. Virology 498:181-191
Hudson, Stephen W; McNally, Mark T (2011) Juxtaposition of two distant, serine-arginine-rich protein-binding elements is required for optimal polyadenylation in Rous sarcoma virus. J Virol 85:11351-60
Van Dusen, Courtney M; Yee, Lily; McNally, Lisa M et al. (2010) A glycine-rich domain of hnRNP H/F promotes nucleocytoplasmic shuttling and nuclear import through an interaction with transportin 1. Mol Cell Biol 30:2552-62
Maciolek, Nicole L; McNally, Mark T (2008) Characterization of Rous sarcoma virus polyadenylation site use in vitro. Virology 374:468-76
McNally, Mark T (2008) RNA processing control in avian retroviruses. Front Biosci 13:3869-83
Maciolek, Nicole L; McNally, Mark T (2007) Serine/arginine-rich proteins contribute to negative regulator of splicing element-stimulated polyadenylation in rous sarcoma virus. J Virol 81:11208-17
Sun, Hai-Yuan; McNally, Mark T; Jackson, Vaughn E et al. (2006) Urea-nuclease treatment of concentrated retrovirions preserves viral RNA and removes polymerase chain reaction-amplifiable cellular RNA and DNA. J Virol Methods 137:304-8
McNally, Lisa M; Yee, Lily; McNally, Mark T (2006) Heterogeneous nuclear ribonucleoprotein H is required for optimal U11 small nuclear ribonucleoprotein binding to a retroviral RNA-processing control element: implications for U12-dependent RNA splicing. J Biol Chem 281:2478-88
Cochrane, Alan W; McNally, Mark T; Mouland, Andrew J (2006) The retrovirus RNA trafficking granule: from birth to maturity. Retrovirology 3:18
Maciolek, Nicole L; Alward, Wallace L M; Murray, Jeffrey C et al. (2006) Analysis of RNA splicing defects in PITX2 mutants supports a gene dosage model of Axenfeld-Rieger syndrome. BMC Med Genet 7:59

Showing the most recent 10 out of 17 publications